Immunis, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2018-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
3
Active:1
Completed:0
Trial Phases
2 Phases
Phase 1:1
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (50.0%)Phase 2
1 (50.0%)INTERMEDIATE-SIZE PATIENT POPULATIONS EXPANDED ACCESS to TREATMENT for SARCOPENIC OBESITY
- Conditions
- SarcopeniaObesity and Obesity-related Medical Conditions
- First Posted Date
- 2025-01-20
- Last Posted Date
- 2025-01-21
- Lead Sponsor
- Immunis, Inc.
- Registration Number
- NCT06784297
Safety and Efficacy of IMM01-STEM Against Placebo on Muscle Performance in Seniors With Obesity and Muscle Weakness
Phase 2
Recruiting
- Conditions
- Muscle PerformanceSarcopenic Obesity
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Immunis, Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT06600581
- Locations
- 🇺🇸
National Institute of Clinical Research (NICR), Pomona, California, United States
🇺🇸Johnson Country Clinical Trials (JCCT), Lenexa, Kansas, United States
🇺🇸Tekton Research, Wichita, Kansas, United States
Safety and Tolerability of IMM01-STEM in Patients With Muscle Atrophy Related to Knee Osteoarthritis.
- First Posted Date
- 2022-01-27
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- Immunis, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT05211986
- Locations
- 🇺🇸
Orthopaedic Specialty Institute, Irvine, California, United States
🇺🇸University of California, Irvine - Alpha Stem Cell Clinic, Orange, California, United States
News
No news found